Intellectual Property

PG490 Patents

The following tables cover granted patents in later phases of research or early development:

Law Firm/

Title

Country

Filing date

Serial No.

Status

Date grantd/ Pat No.

Perkins & Coie

immuno-suppressive compounds and methods

US

03/01/96


08/609,277

Granted

09/02/97


5663335

Perkins & Coie

immuno-suppressive compounds and methods

 US

09/01/98 (int’l)

 
09/142,128

Granted

10/05/99



5962516

Perkins & Coie

immuno-suppressive compounds and methods

AU

02/28/97* (int’l)


2061397

Granted

02/17/00



712241

Perkins & Coie

immuno-suppressive compounds and methods

SG

02/28/97* (int’l)

9804666-7

Granted

11/16/99


56243


PG490 Prodrugs

Law Firm/

Title

Country

Filing date

Serial No.

Status

Date grantd/ Pat No.

Perkins & Coie  

triptolide prodrugs having high aqueous solubility

US

09/02/99


09/389,769

Granted

11/21/00


6150539

Perkins & Coie  

triptolide prodrugs having high aqueous solubility

SG

09/02/99†  

2001010883

Allowed: Grant fee due Sept. 2006

 

 


Research agents

The following table covers patents granted on agents in the early research phase:

Law Firm/

Title

Country

Filing date

Serial No.

Status

Date grantd/ Pat No.

Perkins & Coie

immunotherapy composition and method

US

06/02/94

08/252,953

Granted

12/01/98

5843452

Perkins & Coie

mammalian dna topoisomerase II inhibitor and method

us

03/18/93

08/032,867

Granted

06/20/95

5426224

Perkins & Coie

mammalian dna topoisomerase II inhibitor and method

us

06/05/95

08/471,749

Granted

06/17/97

5639793

Perkins & Coie

tripterinin compound and method

us

03/10/93

08/031,288

Granted

11/21/95

5468772

Perkins & Coie

method for suppressing xenograft rejection

us

06/07/95

08/484,782

Granted

06/02/98

5759550

Perkins & Coie

immuno-suppressant diterpene compound

us

01/19/95

08/375,362

Granted

07/15/97

5648376

Perkins & Coie

antifungal compounds from pseudomonas viridiflava

us

11/26/97

08/978,788

Granted

 

08/15/00

6103875

  

PG490 in Combination

The following table covers patent applications that are under license:

Law Firm/

Title

Country

Filing date

 

Serial No.

Status

Bozicevic, Field & Francis

Uses of Diterpenoid Triepoxides As an Anti-Proliferative Agent

US

8/30/1999

09/385,917

ISSUED as U.S. 6,294,546

Bozicevic, Field & Francis

Uses of Diterpenoid Triepoxides As an Anti-Proliferative Agent

US

6/19/2001

09/884,898

Allowed – Issue Fee Paid

 

Law Firm/

Title

Country

Filing date

 

Serial No.

Status

Bozicevic, Field & Francis

combined therapy of diterpenoid triepoxides and trail for synergistic killing of tumor

US

02/15/00

09/505,250

ISSUED as U.S. 

6,329,148


Intellectual Property In-License

In February 2003, Pharmagenesis, Inc. obtained an exclusive license to these combination inventions to develop, manufacture, and sell in the field of use of therapeutics.  These inventions are useful for treatment of cancer with a combination of Triptolide (PG490) or a related molecule, and an anti-cancer drug, such as, Camptosar® or Navelbine®, and the diagnosis of tumors that are susceptible to such combination.



Trademarks

In the U.S., Pharmagenesis, Inc. has obtained trademark on the name “Pharmagenesis”.  Pharmagenesis, Inc. also is seeking this trademark in the EU. The name “Pharmagenesis” and the design shown below have also been registered as trademarks in China.  

 

 

 

Management ] R&D ] [ IP ] Contact ] Site Map ]

Home ]